Chemical Component Summary

NameCYTARABINE
Synonyms1-BETA-D-ARABINOFURANOSYLCYTOSINE; ARA-C
Identifiers4-amino-1-[(2R,3S,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
FormulaC9 H13 N3 O5
Molecular Weight243.217
TypeNON-POLYMER
Isomeric SMILESC1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O
InChIInChI=1S/C9H13N3O5/c10-5-1-2-12(9(16)11-5)8-7(15)6(14)4(3-13)17-8/h1-2,4,6-8,13-15H,3H2,(H2,10,11,16)/t4-,6-,7+,8-/m1/s1
InChIKeyUHDGCWIWMRVCDJ-CCXZUQQUSA-N

Chemical Details

Formal Charge0
Atom Count30
Chiral Atom Count4
Bond Count31
Aromatic Bond Count6

Drug Info: DrugBank

DrugBank IDDB00987 
NameCytarabine
Groups
  • investigational
  • approved
DescriptionA pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Synonyms
  • Cytarabine liposome
  • cytosine-β-D-arabinofuranoside
  • Cytarabine
  • Cytarabinum
  • Cytosine-1-beta-D-arabinofuranoside
Brand Names
  • Cytarabine Injection
  • Cytarabine Injection, Mylan Std.
  • Aj-cytarabine
  • Vyxeos
  • Cytarabine - Pws 1gn/vial
IndicationFor the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia. Cytarabine is indicated in combination with [daunorubicin] for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.[L32843]
Categories
  • Agents Causing Muscle Toxicity
  • Anti-Infective Agents
  • Antimetabolites
  • Antineoplastic Agents
  • Antineoplastic and Immunomodulating Agents
ATC-Code
  • L01BC01
  • L01XY01
CAS number147-94-4

Drug Targets

NameTarget SequencePharmacological ActionActions
DNA polymerase betaMSKRKAPQETLNGGITDMLTELANFEKNVSQAIHKYNAYRKAASVIAKYP...unknowninhibitor
DNA-unknowncross-linking/alkylation
Cytochrome P450 3A4MALIPDLAMETWLLLAVSLVLLYLYGTHSHGLFKKLGIPGPTPLPFLGNI...unknownsubstrate
Deoxycytidine kinaseMATPPKRSCPSFSASSEGTRIKKISIEGNIAAGKSTFVNILKQLCEDWEV...unknownsubstrate
5'-nucleotidaseMCPRAARAPATLLLALGAVLWPAAGAWELTILHTNDVHSRLEQTSEDSSK...unknownsubstrate
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
Pharos CHEMBL803
PubChem 6253
ChEMBL CHEMBL803
ChEBI CHEBI:28680
CCDC/CSD ARBCYT10